Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
NASDAQ:NKTR
Price:
1.83 USD
3.39%
Market Closed
Updated:
May 16, 2024
Nektar Therapeutics
Income from Continuing Operations
|
Nektar Therapeutics
Income from Continuing Operations Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Income from Continuing Operations
-$175.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is Nektar Therapeutics's Income from Continuing Operations?
Income from Continuing Operations
-175.8m
USD
-175.8m
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Income from Continuing Operations amounts to -175.8m USD.
What is Nektar Therapeutics's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-1%
-1%
Over the last year, the Income from Continuing Operations growth was 58%. The average annual Income from Continuing Operations growth rates for Nektar Therapeutics have been 26% over the past three years , and -1% over the past ten years .
You don't have any saved screeners yet
